Navigation Links
Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
Date:9/12/2007

," said Daniel C. Adelman, M.D., Senior Vice President, Development and Chief Medical Officer at Sunesis.

"We're also excited to be treating patients for the first time with SNS-314, our internally discovered Aurora kinase inhibitor. SNS-314 has shown broad anti-tumor activity across a number of tumor models, and selective and specific activity against Aurora kinases in non-clinical studies," Dr. Adelman continued.

About SNS-595

SNS-595 is currently in Phase 1 and Phase 1b acute leukemia clinical trials and a Phase 2 ovarian cancer clinical trial. SNS-595 is a replication- dependent DNA damaging agent that causes irreversible growth arrest of proliferating cells and rapid apoptosis. In clinical trials conducted to date, SNS-595 has been well tolerated and has shown promising signs of clinical activity in both solid and hematological tumor types. In non- clinical evaluations, SNS-595 demonstrates broad and potent activity in xenograft, syngeneic and drug-resistant models.

About SNS-314

Discovered by Sunesis using the company's discovery platform, SNS-314 is a potent and selective inhibitor of Aurora kinases A, B and C. SNS-314 targets the uncontrolled cellular proliferation associated with cancer by halting cell division at the mitotic phase of the cell cycle. Aurora kinases are key enzymes involved in cancer cell division and have a central role in the abnormal proliferation of tumors.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
2. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
3. Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association
4. Sunesis Presents Data Supporting SNS-032s Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting
5. Sunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
(Date:4/22/2014)... Association for Molecular Pathology (AMP) released a report ... on recommendations for a molecular diagnostics curriculum ... education. The report was prepared by the Medical ... AMP Training and Education Committee. "Our goal was ... medical laboratory scientists appropriately in order to manage ...
(Date:4/22/2014)... the standard measurement for assessing glycemic control over time ... typically measured every few months in a laboratory, but ... estimates A1c using self-monitored blood glucose (SMBG) readings, as ... DTT ), a peer-reviewed journal from Mary Ann Liebert, ... DTT website at http://www.liebertpub.com/dtt . , ...
(Date:4/22/2014)... To help rein in massive health care spending, a ... urgently find ways to incentivize pharmaceutical companies and device ... Instead of examining existing medical technologies and their use, ... affect what drugs and medical devices get created in ... health care spending with as little loss of health ...
(Date:4/22/2014)... ARBOR, Mich. Nearly 7 in 10 Americans ... a new national survey by researchers at the University ... with children under the age of 18 at home, ... more likely than other adults to support universal coverage ... appear in the Journal of the American Medical ...
(Date:4/22/2014)... news release is available in German . ... Perutz Laboratories of the University of Vienna and the Medical ... have now shown how double stranded RNA, such as viral ... cell. During the immune response against viral infection, the protein ... There it modifies viral RNA to inhibit reproduction of the ...
Breaking Medicine News(10 mins):Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3Health News:More than two-thirds of Americans support mandated coverage of birth control in health plans 2Health News:How the body fights against viruses 2Health News:How the body fights against viruses 3
... disease are receiving implantable cardioverter-defibrillators (ICDs) to maintain proper ... the 1980s, but little is known about how well ... 1 percent of recipients. A report in the April ... the largest pediatric experience to date. It finds the ...
... In a major step toward a practical energy ... development of a new generation of sub-microscopic nanomotors that ... motors. Their study is scheduled for the May 27 ... the new study, Joseph Wang and colleagues point out ...
... Campaign Encourages Consumers to Get Active and Give Back By Logging Miles ... ... A healthy lifestyle is always,important and to encourage consumers to get active, ... Breast,Cancer Organization with a donation of up to $200,000. Running from May ...
... Management to Host Conference Call Today at 11:30 a.m. ET ... a provider of liquid nutritional, functional foods, beverages and,nutritional supplements, ... 2008., Financial and operational highlights for First Quarter ... year period to $1.6 million -- Gross profit was ...
... Fla., May 1 Blue Cross and ... David Pizzo has been appointed Market,President - ... http://www.newscom.com/cgi-bin/prnh/20080501/CLTH034 ), (Logo: http://www.newscom.com/cgi-bin/prnh/20000427/BLUELOGOA ... ), Pizzo has served in a ...
... Mich., May 1 Perrigo Company,(Nasdaq: PRGO ... Directors declared a,quarterly dividend of $0.05 per share, ... on May 25, 2008., Perrigo Company is ... distributes over-the-counter (OTC) and prescription,pharmaceuticals, nutritional products, active ...
Cached Medicine News:Health News:Largest study to date finds benefits of ICDs in children 2Health News:Bumble Bee Foods Launches BeeWell Miles; An Interactive Health and Wellness Program Benefitting the Y-Me National Breast Cancer Foundation 2Health News:Bumble Bee Foods Launches BeeWell Miles; An Interactive Health and Wellness Program Benefitting the Y-Me National Breast Cancer Foundation 3Health News:XELR8 Holdings Announces Record First Quarter Revenue 2Health News:XELR8 Holdings Announces Record First Quarter Revenue 3Health News:XELR8 Holdings Announces Record First Quarter Revenue 4Health News:XELR8 Holdings Announces Record First Quarter Revenue 5Health News:XELR8 Holdings Announces Record First Quarter Revenue 6Health News:XELR8 Holdings Announces Record First Quarter Revenue 7Health News:XELR8 Holdings Announces Record First Quarter Revenue 8Health News:David Pizzo Appointed Blue Cross and Blue Shield of Florida Market President - West Florida 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: